Title: Elizabeth Holmes’ Partner Raising Millions for New Startup: NYT
In a surprising turn of events, Billy Evans, the partner of convicted Theranos founder Elizabeth Holmes, is raising millions of dollars for a new biotech startup, according to a report by The New York Times. The startup, called Haemanthus, aims to deliver “human health optimization” through blood testing. This news comes as a shock to many, considering Holmes is currently serving an 11-year sentence for misleading investors with false claims about Theranos’ blood-testing technology.
Haemanthus, which means “blood flower” in Greek, is a biotech startup that is focused on providing personalized health optimization through blood testing. The company has reportedly raised millions of dollars in funding, with Evans at the helm as the CEO. The exact amount of funding is not publicly disclosed, but sources close to the matter have confirmed that it is a significant sum.
It is worth noting that Evans and Holmes have a long history together, dating back to their time at Theranos. Evans served as the company’s chief operating officer, and was a key figure in the development of Theranos’ blood-testing technology. However, it was ultimately Holmes who was found guilty of misleading investors and defrauding patients.
Holmes’ conviction and sentence were a major blow to the biotech industry, and many felt that it would be a long time before she would be able to return to the industry. However, it appears that Evans is moving forward with Haemanthus, and is determined to make a success of the company.
Haemanthus has stated that its goal is to provide personalized health optimization through blood testing, and to help people live healthier and more fulfilling lives. The company is focused on developing new technologies and methods for analyzing blood samples, and is working with a team of experts in the field to achieve this goal.
While Haemanthus is still in its early stages, the company has already made significant progress. The company has reportedly secured partnerships with several major healthcare organizations, and has begun conducting clinical trials for its technology.
In a statement, Evans said, “We are thrilled to be working on this new project, and are excited about the potential it has to make a real difference in people’s lives. We believe that our technology has the potential to revolutionize the way we approach health and wellness, and we are committed to making it a reality.”
It is unclear whether Holmes will be involved with Haemanthus in any capacity, but it is likely that she will have some involvement given her long history with the company. However, it is worth noting that Holmes is currently serving her sentence, and it is unlikely that she will be able to participate in the day-to-day activities of the company.
Regardless of Holmes’ involvement, Haemanthus is a significant development in the biotech industry, and is likely to be closely watched by investors and industry experts alike. The company has the potential to make a real difference in people’s lives, and could be a major player in the healthcare industry for years to come.
In conclusion, the news that Billy Evans is raising millions of dollars for a new biotech startup, Haemanthus, is a significant development in the industry. The company’s goal of providing personalized health optimization through blood testing is ambitious, and could have a major impact on the way we approach health and wellness. While it is unclear whether Holmes will be involved with the company, it is likely that Haemanthus will be a major player in the industry for years to come.
